Market Data
Market Cap₹3,781.49 Cr.
52W High₹685.95
Current Price₹537.1
52W Low₹280
Down from 52W High21.7 %
Face Value₹2
Performance
ROCE11.99 %
ROE11.22 %
EPS (TTM)₹5.89
EPS Prev Qtr₹1.55
EPS Last Year₹-1.69
EBITDA Qtr₹40 Cr.
Book Value₹386
Financial Health
Debt/Equity0.17
Debt/Profit1.54
Total Assets₹3,737.44 Cr.
Promoter Holding70.22 %
Earning Power2.82 %
Valuation
Stock P/E12.41
Industry P/E33.81
Price to Book1.39
Price to Sales1.64
Graham Number₹613.49
Key Metrics
Face Value
₹2
About Unichem Laboratories Ltd
Healthcare · Pharmaceuticals
Unichem Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹3,781.49 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy debt-to-equity ratio of 0.17, indicating low financial risk.
- The P/E ratio of 12.11 suggests the stock may be undervalued relative to earnings.
- The P/B ratio of 1.36 indicates the market values the company slightly above its book value.
- ROCE of 11.99% shows efficient use of capital to generate profits.
- ROE of 11.22% reflects strong returns generated for shareholders.
Weaknesses
- The company does not currently offer a dividend yield.
- With a promoter holding of 70.22%, there may be concerns about minority shareholder influence.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 578.96 | 521.17 | 575.12 | 632.62 |
| ↳ QoQ Growth | - | -10.0% | +10.4% | +10.0% |
| Expenses | 544.25 | 507.64 | 558.05 | 592.62 |
| Operating Profit | 34.71 | 13.53 | 17.07 | 40 |
| OPM % | 6% | 2.6% | 2.97% | 6.32% |
| Other Income | 20.97 | 11.8 | 23.47 | 15.61 |
| Interest | 8.24 | 7.42 | 9.39 | 6.62 |
| Depreciation | 31.47 | 31.25 | 30.61 | 29.94 |
| EBITDA | 66.18 | 44.78 | 47.68 | 69.94 |
| EBITDA Margin % | 11.43% | 8.59% | 8.29% | 11.06% |
| Profit Before Tax | -10.82 | 293.43 | 18.79 | 48.99 |
| Tax % | -9.89% | 9.93% | 41.94% | 15.35% |
| Net Profit | -11.89 | 264.29 | 10.91 | 41.47 |
| ↳ QoQ Growth | - | +2322.8% | -95.9% | +280.1% |
| EPS | -1.69 | 37.54 | 1.55 | 5.89 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 14.08 | 14.08 |
| Reserves | 2436.51 | 2703.36 |
| Borrowings | 459.77 | 468.78 |
| Other Liabilities | 659.04 | 551.22 |
| Total Liabilities | 3569.4 | 3737.44 |
| Fixed Assets | 1279.32 | 1212.58 |
| CWIP | 30.67 | 100.14 |
| Investments | 0.02 | 0.02 |
| Other Assets | 2259.39 | 2424.7 |
| Total Assets | 3569.4 | 3737.44 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 3.64 |
| Cash from Investing Activity | 192.06 |
| Cash from Financing Activity | 1.86 |
| Net Cash Flow | 197.56 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 70.22% | 70.22% | 70.22% | 70.22% |
| FIIs % | 1% | 0.99% | 1% | 0.91% |
| DIIs % | 10.74% | 10.74% | 10.64% | 10.46% |
| Public % | 15.26% | 15.18% | 15.22% | 15.59% |
| No. of Shareholders | 23,577 | 23,267 | 23,386 | 25,347 |
Major Shareholders (>1%)
- Ipca Laboratories LimitedPromoter and Promoter Group52.67%
- Dr. Prakash Amrut ModyPromoter and Promoter Group12.78%
- Hdfc Small Cap FundPublic Shareholding7.75%
- Anita Prakash ModyPromoter and Promoter Group1.88%
As of 2026-06-30View all shareholders →